{
  "docId": "019de076-b7ca-70fb-95b8-5a74e3aefffe",
  "docSlug": "5062b9a9257606648ea145bccd66e04d",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 41 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 9,
  "pageCount": 41,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "balanced",
  "nDataPoints": 12,
  "notes": "The slide uses a structured table to highlight gaps in current treatment standards.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/9",
  "deckHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe",
  "deckJsonHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe.json",
  "deckAnchorHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.05,
        "y": 0.85
      },
      "kind": "source-note",
      "text": "* Repotrectinib was approved November 2023; ** Not FDA approved, but in NCCN guidelines. 1L, 1st line; 2L, 2nd line; 3L, 3rd line; CNS, central nervous system. Sources (ALK): ... Sources (ROS1): ...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5981e236-4f0a-4b16-ba07-628eb562b325",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.52,
        "w": 0.82,
        "x": 0.09,
        "y": 0.31
      },
      "kind": "table",
      "text": "Comparison table of ALK+ and ROS1+ NSCLC treatment landscapes",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aa751a3e-8208-48c4-915e-570337181b72",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.9,
        "x": 0.05,
        "y": 0.18
      },
      "kind": "title",
      "text": "Emerging resistance mutations, increasing CNS involvement, and treatment-related adverse events limit utility of approved therapies",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c284bb79-9c77-4c5f-aeb6-d713a0517bd9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.05,
        "y": 0.11
      },
      "kind": "title",
      "text": "ALK+ and ROS1+ NSCLC Landscape",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "59237b1b-3b35-4ca0-bb71-b060547308e4",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison-frame",
      "slug": null,
      "matchId": "8f196fb1-d8e5-4143-bf14-9e3d4357bb21",
      "evidence": "The slide compares two distinct clinical landscapes (ALK+ and ROS1+) side-by-side using identical metrics.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 9,
      "from": 9,
      "beatId": "7c3004c9-d14e-4ddd-ac8b-469b44ef6e17",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "The document presents the problem of emerging resistance mutations, increasing CNS involvement, and treatment-related adverse events in current cancer therapies.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 11,
      "from": 9,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "7394c275-2e8b-4ce7-ac85-c375b43f1f48",
      "evidence": "The document highlights the limitations of current therapies and the potential benefits of Nuvalent's solutions.",
      "position": 0,
      "objective": "What are the consequences of not addressing the limitations of current cancer therapies?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}